ACTN3

Across TCGA pan-cancer cohorts, ACTN3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACTN3 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ACTN3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ACTN3 expression acts as an unfavorable survival marker.

HNSC, OV, and CCRCC are the cancer types where ACTN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.954	1.000	.016	9	view →
OV	DFS	Median	All	0.593	1.000	.036	8	view →
CCRCC	DFS	Quartile	III,IV	0.158	0.887	.024	8	view →
LUAD	OS	Median	II,III,IV	0.307	0.911	.001	8	view →
LSCC	DFS	Tertile	All	0.331	1.000	.006	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACTN3–HNSC (OS)

Open the HNSC breakdown →